Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202411054 A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers New Drug Phase Ⅰ
N202411061 A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis New Drug Phase Ⅲ
N202412029 A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure New Drug Phase Ⅲ
N202412037 A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) New Drug Phase Ⅱ
N202501016 A preliminary bioequivalence study to compare two sildenafil citrate orally disintegrating tablets in healthy male subjects under fasted state. Bioavailability / Bioequivalence (BA/BE) NA
N202501025 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma New Drug Phase Ⅲ
N202501029 “DeepRad.AI”DeepLung-BMD Clinical Validation New Medical Device NA
N202501031 Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) New Drug Phase Ⅲ
N202501032 A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects with Hyperuricemia with or without Chronic Kidney Disease New Drug Phase Ⅰ
N202502002 A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases New Drug Phase Ⅲ
1 2 21 22 23 24 25 26 27 51 52 / 52

TOP